Sotigalimab
Diffuse Intrinsic Pontine Gliomas (DIPG)
Pediatric Brain Tumor Consortiummonoclonal_antibodyPhase 1Active
CC
42/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 27/ 100
- Competitive Position
- 95/ 100
Competitive context
27 Active assets in the Diffuse Intrinsic Pontine Gliomas (DIPG) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Actuate Therapeutics Inc. | Phase 2 | BB |
(+)-VINCRISTINE Julie Krystal | Phase 2 | B |
Valproic Acid University of Göttingen | Phase 3 | B |
ETOPOSIDE Theodore S. Johnson | Phase 2 | B |
Indoximod Theodore S. Johnson | Phase 2 | B |
View all 42 →
Same molecule, other indications
Sotigalimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →